Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$1.25M-$1.25MN/M vs Q2 2025 EPS Diluted-$0.08-$0.08N/M vs Q2 2025 Operating Income-$1,211,491N/M Operating Cash Flowderived-$1,393,955N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end